New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?

References

• Perz J, Armstrong G, Farrington L, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
   PubMed Web of Science ®Google Scholar
• Arzumanyan A, Reis HMGPV, Feitelson M. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–135.
   PubMed Web of Science ®Google Scholar
• Giannini E, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61:184–190.
   PubMed Web of Science ®Google Scholar
• Lind PA, Naucler G, Holm A, et al. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Acta Oncol (Madr). 2007;46:230–233.
   PubMed Web of Science ®Google Scholar
• Mok TS, Leung TW, Lee SD, et al. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999;44:307–311.
   PubMed Web of Science ®Google Scholar
• Hezel A, Zhu A. Systemic therapy for biliary tract cancers. Oncologist. 2008;13:415–423.
   PubMed Web of Science ®Google Scholar
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Yeo W, Mok T, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532–1538.
   PubMed Web of Science ®Google Scholar
• Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang W-T, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Lin D-Y, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–4075.
   PubMed Web of Science ®Google Scholar
• Bruix J, Tak W-Y, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412–3419.
   PubMed Web of Science ®Google Scholar
• Bruix J, Merle P, Granito A, et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Ann Oncol. 2016;27:ii140–ii1.
   Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet. 2013;14:55–63.
   PubMed Web of Science ®Google Scholar
• Zopf D, Heinig R, Schuetz G, et al. Regorafenib (BAY 73-4506): identification of clinically relevant metabolites and their preclinical pharmacology. 101st Annual Meeting of AACR. 2010;Abstract 1666.
   Google Scholar
• Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–2667.
   PubMed Web of Science ®Google Scholar
• FDA. Drug safety information: This link exits the ClinicalTrials.gov site The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib. 2013 available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm355781.htm.
   Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–1727.
   PubMed Web of Science ®Google Scholar
• Eisen T, Joensuu H, Nathan P, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet. 2012;13:1055–1062.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;16:619–629.
   PubMed Web of Science ®Google Scholar
• Demetri G, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2013;381:295–302.
   PubMed Web of Science ®Google Scholar
• Argilés G, Saunders M, Rivera F, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. Eur J Cancer. 2015;51:942–949.
   PubMed Web of Science ®Google Scholar
• Huynh H, Nguyen TTT, Chow K-HP, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.
   PubMed Web of Science ®Google Scholar
• Llovet J, Di Bisceglie A, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet J Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease. 2010;30:52–60.
   Google Scholar
• Spratlin J, Cohen R, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–787.
   PubMed Web of Science ®Google Scholar
• Zhu A, Finn R, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19:6614–6623.
   PubMed Web of Science ®Google Scholar
• Garcia J, Hudes G, Choueiri T, et al. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014;120:1647–1655.
   PubMed Web of Science ®Google Scholar
• Zhu A, Park J, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet. 2015;16:859–870.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib. https://clinicaltrialsgov/ct2/show/NCT02435433.
   Google Scholar
• Boccaccio C, Comoglio P. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6:637–645.
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103.
   PubMed Web of Science ®Google Scholar
• Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1544–1553.
   PubMed Web of Science ®Google Scholar
• Santoro A, Simonelli M, Rodriguez Lope C, et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer. 2013;108:21–24.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Sosman J, Santoro A, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2015;33:159–168.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Abbadessa G, Personeni N, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 2016 cited 2016 Aug 25. DOI:10.18632/oncotarget.1621
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase 3, randomized, double-blind study of tivantinib (ARQ 197) in subjects with MET diagnostic-high inoperable hepatocellular carcinoma treated with one prior systemic therapy. http://clinicaltrialgov/ct2/show/NCT01755767.
   Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298–2308.
   PubMed Web of Science ®Google Scholar
• Cohn AL, Kelley RK, Yang T-S, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30:Abstract 261.
   Google Scholar
• Schimmoller F, Zayzafoon M, Chung LWK, et al. Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol Cancer Ther. 2011;10:Abstract A233.
   Google Scholar
• Mohammad KS, John SK, Xianghong P. Cabozantinib reduces breast cancer bone metastases and improves survival in a mouse mode. IBMS Bonekey. 2012;193:Abstract S14.
   Google Scholar
• Verslype C, Cohn AL, Kelley RT, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase 2 randomized discontinuation trial (RDT). J Clin Oncol. 2012;30:Abstract 4007.
   Google Scholar
• ClinicalTrials.gov. A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib. https://clinicaltrialsgov/ct2/show/NCT01908426.
   Google Scholar
• ClinicalTrials.gov. A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment. https://clinicaltrialsgov/ct2/show/NCT02115373.
   Google Scholar
• Stauffer J, Scarzello A, Jiang Q, et al. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology. 2012;56:1567–1574.
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: a meta-analysis. Plos One. 2015;10:e0131403–e.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–88.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp K, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Motzer R, Escudier B, McDermott D, et al. Nivolumab versus everolimus in advanced renal-cell Carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AMI, Crocenzi T, Welling T, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015;33:abstr LBA101.
   Google Scholar
• Sangro B, Melero I, Yau T, et al. Safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study. J Clin Oncol. 2016;34: Abstract 4078.
   Google Scholar
• ClinicalTrials.gov. A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459). https://clinicaltrialsgov/ct2/show/NCT02576509.
   Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–4293.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224). https://clinicaltrialsgov/ct2/show/NCT02702414.
   Google Scholar
• ClinicalTrials.gov. A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240). https://clinicaltrialsgov/ct2/show/NCT02702401.
   Google Scholar
• Shao -Y-Y, Wu C-H, Lu L-C, et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol. 2014;60:313–318.
   PubMed Web of Science ®Google Scholar
• Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58:2023–2031.
   PubMed Web of Science ®Google Scholar
• Granito A, Marinelli S, Terzi E, et al. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis. 2015;47:518–522.
   PubMedGoogle Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894.
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616–622.
   PubMed Web of Science ®Google Scholar
• Zamarin DPM. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther. 2015;150:23–32.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison J. The future of immune checkpoint therapy. Science. 2015;348:56–61.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy. https://clinicaltrialsgov/ct2/show/NCT01658878.
   Google Scholar
• Lichty B, Breitbach C, Stojdl D, et al. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559–567.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Tong A, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Therapy. 2010;18:429–434.
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–336.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem M, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619–2626.
   PubMed Web of Science ®Google Scholar